Should You Buy Entrada Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Entrada Therapeutics, Inc. (TRDA) carries a solid Quality of Company rating of 5.7/10. Trading at $6.88, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 0 of 1 CirclFi valuation models project upside for Entrada Therapeutics, Inc. (TRDA) at $6.88 — the model consensus leans bearish, with a Quality Score of 5.7/10 and Value-Trap risk of 28/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Entrada Therapeutics, Inc. (TRDA) in 2026?
What Is the Bull Case vs the Bear Case for Entrada Therapeutics, Inc. (TRDA)?
| Bull case | Bear case — $0.35 target (-94.9%) |
|---|---|
| No active model projects meaningful upside for TRDA at $6.88. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.35 (-94.9%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry headwind: dilutive capital raises represents a meaningful risk for Entrada Therapeutics, Inc. and its Biotechnology peers. |
How Does TRDA Compare to Its Biotechnology Peers?
Valuation data pages: SXTP · MGX · GOVX · WHWK · BBOT · LITS · LXEO · GUTS · TGTX · EXEL · INCY
Which Other Stocks Score Like TRDA on Quality?
Closest companies to TRDA’s Quality of Company score of 5.7/10, across all industries.
- LQMT — Liquidmetal Technologies, Inc. (QOC 5.7) · analysis
- CIIT — Tianci International, Inc. (QOC 5.7) · analysis
- FLZH — Flash Sports & Media Holdings, Inc. (QOC 5.7) · analysis
- FCHL — Fitness Champs Holdings Limited (QOC 5.7) · analysis
- EFOI — Energy Focus, Inc. (QOC 5.7) · analysis
- TLSI — TriSalus Life Sciences, Inc. (QOC 5.7) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does TRDA Appear In?
So Is Entrada Therapeutics, Inc. (TRDA) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Entrada Therapeutics, Inc. at $6.88. 1/1 models flag overvaluation, median fair value sits at $0.35 (-94.9%), and the risk-reward profile appears unfavorable. Quality at 5.7/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Entrada Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About TRDA Stock?
Should I buy TRDA stock right now?
Based on CirclFi's multi-model analysis, 0 of 1 models see upside for TRDA at $6.88. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Entrada Therapeutics, Inc.?
Key risks include: limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does TRDA compare to its competitors?
Among Biotechnology peers, TRDA holds a Quality Score of 5.7/10. Comparable companies include SXTP (QOC 5.7), MGX (QOC 5.7), GOVX (QOC 5.7). The relative ranking helps investors identify whether TRDA offers better fundamental quality than alternatives in the same sector.
Is TRDA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. TRDA's Quality Score of 5.7/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy TRDA at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $0.35 to $0.35. At $6.88, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for TRDA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad